Genmab Kept at Buy as Truist Securities Forecasts 'Transformative' Year Ahead

09:34 AM EST, 12/30/2025 (MT Newswires) -- Truist Securities reiterated its buy rating on Genmab (GMAB.CO) amid a model update following the company's decision to discontinue further clinical development of its investigational cancer therapy acasunlimab after a portfolio review. "While we are disappointed with this update, we are not entirely surprised, given the most recent data presented at ESMO IO. But Acasun was secondary, and we remain focused on the transformative year ahead for Genmab, with 5-6 pivotal trial readouts for Epkinly, Rina-S & Peto," the research firm said in a Tuesday note. "We continue to view GMAB as a good investment, as the company is evolving into a multi-franchise commercial biotech - with three launched / late-stage assets with blockbuster potential." Analysts are also bullish on their outlook for Genmab, viewing the next 12 to 18 months as "possibly the most transformative period" in the Danish biotechnology company's history. The stock's price target was left unchanged at $48.